Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Baumann Kreuziger, Lisa M ^a   Keenan, Joseph C ^a   Morton, Colleen T ^a   Dries, David J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 9 COMPLEX; DABIGATRAN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBOCYTE CONCENTRATE; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HUMAN; REVIEW; THROMBOCYTE TRANSFUSION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); HEMORRHAGE; RISK FACTOR;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; DABIGATRAN; FACTOR VIIA; HEMORRHAGE; HUMANS; PYRAZOLES; PYRIDONES; RISK FACTORS;

EID: 84931325490     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/583794     Document Type: Review

References (48)

1. F. Kazmier, J. A. Spittel, J. J. Thompson, and C. A. Owen, " Effect of oral anticoagulation on factors VII, IX, X, and II, " Archives of Internal Medicine, vol. 115, pp. 667-673, 1965.
2. J. van Ryn, J. Stangier, S. Haertter, et al., "Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, " Thrombosis & Haemostasis, vol. 103, no. 6, pp. 1116-1127, 2010.
3. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, "Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development, " Clinical Pharmacokinetics, vol. 48, pp. 1-22, 2009.
4. P. C. Wong, D. J. P. Pinto, and D. Zhang, "Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor, " Journal of Thrombosis and Thrombolysis, vol. 31, no. 4, pp. 478-492, 2011.
5. D. M. Siegal, D. A. Garcia, and M. A. Crowther, "How I treat target-specific oral anticoagulant-associated homorrhage, " Blood, vol. 123, pp. 1152-1158, 2014.
6. M. R. Southworth, M. E. Reichman, and E. F. Unger, "Dabigatran and postmarketing reports of bleeding, " The New England Journal of Medicine, vol. 368, no. 14, pp. 1272-1274, 2013.
7. K. M. Bruins Slot and E. Berge, "FactorXa inhibitors vswarfarin for preventing stroke and thromboembolism in pateints with atrial fibrillation, " JAMA, vol. 311, pp. 1150-1151, 2014.
8. G. Stepanyan, N. Badhwar, R. J. Lee, et al., "Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation, " Journal of Interventional Cardiac Electrophysiology, vol. 40, pp. 33-38, 2014.
9. Baxter, FEIBA prescribing information 2011.
10. CSL Behring GmbH, "Kcentra prescribing information, " http://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf.
11. Novo Nordisk Inc, NovoSeven RT Coagulation Factor VIIa Prescribing Information, 1999.
12. R. Meehan, M. Tavares, and J. Sweeney, "Clinical experience with oral versus intravenous vitamin K for warfarin reversal (CME), " Transfusion, vol. 53, no. 3, pp. 491-498, 2013.
13. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Cracowski, and G. Pernod, "Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers, " Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217-224, 2012.
14. J. van Ryn, J. Schurer, M. Kink-Eiband, and A. Clemens, "The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation, " Blood, vol. 118, p. 2316, 2011.
15. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, "Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, " Circulation, vol. 124, no. 14, pp. 1573-1579, 2011.
16. J. van Ryn, D. Ruehl, H. Priepke, H. Hauel, and W. Wienan, "Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate, " Haematologica, vol. 93, p. 148, 2008.
17. T. Warkentin, P. Margetts, S. Connolly, A. Lamy, C. Ricci, and J. Eikelboom, "Recombinant factor VIIa (rFVIIa) and hemodialysis tomanage massive dabigatran-associated postcardiac surgery bleeding, " Blood, vol. 119, pp. 2172-2174, 2012.
18. S. T. Garber, W. Sivakumar, and R. H. Schmidt, "Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran, " Journal of Neurosurgery, vol. 116, no. 5, pp. 1093-1096, 2012.
19. E. Truumees, T. Gaudu, C. Dieterichs, M. Geck, and J. Stokes, "Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on pradaxa (dabigatran), " Spine, vol. 37, pp. E863-E865, 2012.
20. A. Lillo-Le Louet, M. Wolf, L. Soufir, et al., "Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation, " Thrombosis and Haemostasis, vol. 108, no. 3, pp. 583-585, 2012.
21. S. Schulman, B. Ritchie, J. K. Goy, S. Nahirniak, M. Almutawa, and S. Ghanny, "Activated prothrombin complex concentrate for dabigatran-associated bleeding, " British Journal of Haematology, vol. 164, pp. 296-310, 2013.
22. G. Dickneite and M. Hoffman, "Reversing the new oral anticoagulants with prothrombin comlpex concentrates (PCCs): what is the evidence?"Thrombosis and Haemostasis, vol. 111, no. 2, pp. 189-198, 2014.
23. G. Escolar, J. Reverter, J. Villalta, V. Sanz, P. Molina, and M. Diaz-Ricart, "Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: Studies in vitro with circulating human blood, " Circulation, vol. 126, p. 521, 2012.
24. D. J. Dries, "The contemporary role of blood products and components used in trauma resuscitation, " Scand inavian Journal of Trauma, Resuscitation and Emergency Medicine, vol. 18, no. 1, article 63, 2010.
25. C. Li, J. Hirsh, C. Xie, M. A. Johnston, and J. W. Eikelboom, "Reversal of the anti-platelet effects of aspirin and clopidogrel, " Journal of Thrombosis and Haemostasis, vol. 10, no. 4, pp. 521-528, 2012.
26. T. Thiele, A. Sumnig, G. Hron, et al., "Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study, " Journal of Thrombosis and Haemostasis, vol. 10, pp. 968-971, 2012.
27. Janssen Pharmaceuticals Inc, "Xarelto prescribing information, " 2011.
28. Bristol-Myers Squibb, "Eliquis (apixiban) prescribing information, " 2012, http://packageinserts.bms.com/pi/pi-eliquis. pdf.
29. L. M. Baumann Kreuziger and M. T. Reding, "Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices, " Thrombosis Research, vol. 132, no. 2, pp. e161-e163, 2013.
30. M. E. Kutcher, B. J. Redick, R. C. McCreery, et al., "Characterization of platelet dysfunction after trauma, " Journal of Trauma and Acute Care Surgery, vol. 73, pp. 13-19, 2012.
31. D. Bolliger, M. D. Seeberger, and K. A. Tanaka, "Principles and practice of thromboelastography in Clinical Coagulation Management and Transfusion Practice, " Transfusion Medicine Reviews, vol. 26, no. 1, pp. 1-13, 2012.
32. V. A. Ferraris, A. C. Bernard, B. Hyde, and P. A. Kearney, "The impact of antiplatelet drugs on trauma outcomes, " Journal of Trauma and Acute Care Surgery, vol. 73, no. 2, pp. 492-497, 2012.
33. B. Joseph, V. Pandit, M. Sadoun, et al., "A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage, " Journal of Trauma and Acute Care Surgery, vol. 75, pp. 900-994, 2013.
34. D. K. Nishijima, S. Zehtabchi, J. Berrong, and E. Legome, "Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review, " Journal of Trauma and Acute Care Surgery, vol. 72, pp. 1658-1663, 2012.
35. J. N. Harr, E. E. Moore, J. Johnson, et al., "Antiplatelet therapy is not associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients, " Critical Care Medicine, vol. 41, pp. 399-404, 2013.
36. K. A. Peck, R. Y. Calvo, M. S. Schechter, et al., "The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury, " Journal of Trauma and Acute Care Surgery, vol. 76, pp. 431-436, 2014.
37. J. L. Gordon, T. C. Fabian, M. D. Lee, and M. Dugdale, "Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies, " The Journal of Trauma and Acute Care Surgery, vol. 75, no. 3, pp. 475-486, 2013.
38. M. D. Lambourne, L. J. Eltringham Smith, S. Gataiance, D. M. Arnold, M. A. Crowther, and W. P. Sheffield, "Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate, " Journal of Thrombosis and Haemostasis, vol. 10, no. 9, pp. 1830-1840, 2012.
39. I. Pragst, S. H. Zeitler, B. Doerr, et al., "Reversal of dabigatran anticoagulation by prothrombin complex concentrate (beriplex P/N) in a rabbitmodel, " Journal of Thrombosis and Haemostasis, vol. 10, no. 9, pp. 1841-1848, 2012.
40. W. Zhou, S. Schwarting, S. Illanes, et al., "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran, " Stroke, vol. 42, pp. 3594-3599, 2011.
41. T.-L. Khoo, C. Weatherburn, G. Kershaw, C. J. Reddel, J. Curnow, and S. Dunkley, "The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran, " International Journal of Laboratory Hematology, vol. 35, no. 2, pp. 222-224, 2013.
42. M. K. Wychowski and P. Kouides, "Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment, " Annals of Pharmacotherapy, vol. 46, no. 4, article e10, 2012.
43. L. E. Dumkow, J. R. Voss, M. Peters, and D. L. Jennings, "Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma, " American Journal of Health-System Pharmacy, vol. 69, no. 19, pp. 1646-1650, 2012.
44. E. Perzborn and H. Tinel, "Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats, " Journal of Thrombosis and Haemostasis, vol. 7, article 183, 2009.
45. A. Godier, A. Miclot, B. Le Bonniec, et al., "Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model, " Anesthesiology, vol. 116, pp. 94-102, 2012.
46. E. Perzborn, A. Gruber, H. Tinel, et al., "Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates, " Thrombosis and Haemostasis, vol. 110, no. 1, pp. 162-172, 2013.
47. J. Dinkelaar, P. J. Molenaar, M. Ninivaggi, B. de Laat, H. J. M. Brinkman, and A. Leyte, "In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban, " Journal of Thrombosis and Haemostasis, vol. 11, no. 6, pp. 1111-1118, 2013.
48. M. Korber, E. Langer, S. Ziemer, E. Perzborn, C. Gericke, and C. von Heymann, "Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study, " Clinical and AppliedThrombosis/Hemostasis, 2013.